The evolving first-line treatment of advanced non-small cell lung cancer harbouring epidermal growth factor receptor mutations

The current standard first-line treatment for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harbouring an epidermal growth factor receptor (EGFR) mutation is a first or second-generation EGFR tyrosine kinase inhibitor (TKI) (1,2).